Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report.

Introduction: Vaginal cancer is a rare yet aggressive cancer, with unmet need for novel therapeutics.

Case Presentation: In this case report, we present a patient with advanced stage, HPV-positive vaginal cancer who demonstrated clinical, radiological, and molecular response to combination treatment of antibody-drug conjugate enfortumab vedotin (EV) with pembrolizumab.

Conclusion: This is the first reported response to this combination therapy in vaginal cancer in the literature. The patient had positive Nectin-4 staining on evaluation, raising the possibility for future clinical application of EV in vaginal squamous cell cancer.